NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
NR 547
PMHNP — Psychiatric Mental Health Nurse
Practitioner
CHAMBERLAIN UNIVERSITY
MIDTERM & FINAL EXAM PREP | 2026 LATEST TEST BANK
Brand New • A-Grade • Most Difficult Questions • Verified Answers
30 Advanced Multiple-Choice Questions | Detailed Explanations | Clinical Pearls
15 Midterm Questions + 15 Final Exam Questions
Course NR 547 — Advanced Psychopathology and Psychopharmacology
Program PMHNP — Psychiatric Mental Health Nurse Practitioner (Post-Master's Certificate)
Institution Chamberlain University, College of Nursing
Exam Coverage Midterm (Q1–Q15) and Final Exam (Q16–Q30)
Psychopathology, Psychopharmacology, DSM-5-TR, Therapeutic Modalities, Legal/Ethics,
Content Areas
Special Populations
Format Multiple-choice, clinical vignette-based, advanced reasoning
Edition 2026 — Reflects Current DSM-5-TR, APA, FDA, and Evidence-Based Guidelines
NR 547 Advanced Psychopathology & Psychopharmacology | Page 1 | © Chamberlain PMHNP Study Series
,NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
HOW TO USE THIS EXAM PREP
• Each question is written at the advanced clinical reasoning level expected on the Chamberlain NR 547 Midterm and Final
Examinations.
• Read each vignette carefully before selecting an answer. Clinical scenarios include labs, vitals, DSM-5-TR criteria, and
comorbidities.
• The correct answer (highlighted in green with ✔) is followed by a detailed RATIONALE explaining the clinical reasoning for
correct and incorrect choices.
• A CLINICAL PEARL after each question provides high-yield exam anchors, drug comparison tables, and
DSM-5-TR/guideline references.
• All content reflects current DSM-5-TR criteria, APA Practice Guidelines, FDA approvals, SAMHSA recommendations, and
major psychiatric literature (2026).
CONTENT DOMAINS — MIDTERM & FINAL
Exam Section Content Domain Questions
Midterm Psychiatric Assessment & Differential Diagnosis Q1, Q29
Midterm Psychopharmacology — Antidepressants & Safety Q2, Q13
Midterm Bipolar Spectrum & Mood Stabilizers Q3
Midterm Schizophrenia & First-Episode Psychosis Q4
Midterm Anxiety Disorders — GAD, PTSD, OCD Q5, Q6, Q11
Midterm ADHD — Adult Diagnosis & Management Q7
Midterm Personality Disorders — BPD & DBT Q8
Midterm Substance Use Disorders — MOUD & OUD Q9
Midterm Neurocognitive Disorders — BPSD Q10
Midterm Child & Adolescent Psychiatry — ASD Q12
Midterm Legal/Ethical — Tarasoff & Duty to Protect Q14
Midterm Reproductive Psychiatry — Perinatal Mental Health Q15
Final Antipsychotic Metabolic Syndrome Management Q16
Final Suicide Risk Assessment & Crisis Intervention Q17
Final Treatment-Resistant Depression — Esketamine Q18
Final Perimenopausal/Late-Life Depression Q19
Final Clozapine REMS & Monitoring Q20
NR 547 Advanced Psychopathology & Psychopharmacology | Page 2 | © Chamberlain PMHNP Study Series
,NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
Final Tourette's Disorder & Tic Disorders Q21
Final Sleep Disorders — CBT-I & Orexin Antagonists Q22
Final Geriatric Psychiatry — Delirium vs. Psychosis Q23
Final Consultation-Liaison — Drug Interactions Q24
Final Cultural Psychiatry & CFI Q25
Final Lithium Toxicity & Emergency Management Q26
Final Group Therapy — Crisis & Yalom Factors Q27
Final Collaborative Care Model (CoCM) Q28
Final Advanced Differential — FTD Pharmacotherapy Q29
Final NMS — Recognition & Emergency Management Q30
■ MIDTERM EXAM QUESTIONS (Q1 – Q15) | Advanced Clinical Reasoning
● CATEGORY: PSYCHIATRIC ASSESSMENT & DIAGNOSTIC REASONING
Q1 [MIDTERM] A 34-year-old female presents with a 3-week history of depressed mood,
anhedonia, 12-pound weight loss, early morning awakening, psychomotor retardation,
fatigue, and recurrent thoughts of death without active suicidal plan. She denies any
prior manic or hypomanic episodes. PHQ-9 score is 22 (severe). Which DSM-5-TR
diagnosis is MOST accurate, and what specifier applies?
CLINICAL SCENARIO: PMH: None. No current medications. No substance use. TSH, CBC, CMP
all within normal limits. No psychotic features.
A) Persistent Depressive Disorder (Dysthymia) with anxious distress specifier — chronicity without
episodic course
✔ B) Major Depressive Disorder, Single Episode, Severe, with melancholic features
C) Bipolar II Disorder, current episode depressed — must rule out before diagnosing MDD
D) Adjustment Disorder with Depressed Mood — triggered by unidentified psychosocial stressor
✔ CORRECT ANSWER: B
DETAILED RATIONALE:
This patient meets full DSM-5-TR criteria for Major Depressive Episode (MDE): 5+ symptoms present nearly
every day for >2 weeks including depressed mood AND anhedonia (core symptoms), plus weight loss,
NR 547 Advanced Psychopathology & Psychopharmacology | Page 3 | © Chamberlain PMHNP Study Series
, NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
insomnia (early morning awakening), psychomotor retardation, fatigue, and recurrent thoughts of death.
PHQ-9 of 22 = severe. The presence of melancholic features is indicated by: (1) loss of pleasure in nearly all
activities (anhedonia), (2) lack of mood reactivity, (3) early morning awakening, (4) psychomotor retardation,
(5) significant anorexia/weight loss, and (6) distinct quality of depressed mood (qualitatively different from
grief). These features warrant the 'with melancholic features' specifier. Persistent Depressive Disorder
requires ≥2 years of depressed mood (not 3 weeks). Bipolar II requires documented hypomanic episodes —
the history denies these (though ruling out is clinically important, the answer reflects the correct diagnosis
given available information). Adjustment Disorder requires an identifiable stressor AND symptoms that do
not meet criteria for another disorder — this patient meets full MDE criteria.
★ CLINICAL PEARL & EXAM TIP: DSM-5-TR MDE = 5+ symptoms, ≥2 weeks, including depressed mood
AND/OR anhedonia. Melancholic specifier = anhedonia + ≥3 of: distinct mood quality, mood worse in AM, early
morning awakening (≥2h early), marked psychomotor change, significant anorexia/weight loss, excessive guilt.
PHQ-9 severity: 5–9=mild, 10–14=moderate, 15–19=moderately severe, ≥20=severe.
● CATEGORY: PSYCHOPHARMACOLOGY — ANTIDEPRESSANTS
Q2 [MIDTERM] A 28-year-old male with MDD, severe, is started on sertraline 50 mg daily.
At his 2-week follow-up, he reports no improvement in mood but notes significant
improvement in sleep and appetite. His Columbia Suicide Severity Rating Scale
(C-SSRS) score has increased from baseline. He reports 'I finally have enough energy to
do something about how I feel.' Which of the following MOST accurately describes this
clinical situation and the PMHNP's priority action?
CLINICAL SCENARIO: C-SSRS: Ideation intensity increased. No specific plan reported at
intake. Energy reportedly improved before mood.
A) This is expected SSRI activation — reassure the patient and continue sertraline at the current
dose
✔ B) This represents a dangerous transition window: energy recovery preceding mood
recovery increases suicide risk; perform immediate risk stratification, safety planning, and
consider hospitalization
C) The sertraline is likely not working — switch immediately to venlafaxine XR, an SNRI with faster
onset
D) Add a benzodiazepine for anxiety and schedule follow-up in 4 weeks as sertraline requires 6–8
weeks for full effect
✔ CORRECT ANSWER: B
DETAILED RATIONALE:
NR 547 Advanced Psychopathology & Psychopharmacology | Page 4 | © Chamberlain PMHNP Study Series
NR 547
PMHNP — Psychiatric Mental Health Nurse
Practitioner
CHAMBERLAIN UNIVERSITY
MIDTERM & FINAL EXAM PREP | 2026 LATEST TEST BANK
Brand New • A-Grade • Most Difficult Questions • Verified Answers
30 Advanced Multiple-Choice Questions | Detailed Explanations | Clinical Pearls
15 Midterm Questions + 15 Final Exam Questions
Course NR 547 — Advanced Psychopathology and Psychopharmacology
Program PMHNP — Psychiatric Mental Health Nurse Practitioner (Post-Master's Certificate)
Institution Chamberlain University, College of Nursing
Exam Coverage Midterm (Q1–Q15) and Final Exam (Q16–Q30)
Psychopathology, Psychopharmacology, DSM-5-TR, Therapeutic Modalities, Legal/Ethics,
Content Areas
Special Populations
Format Multiple-choice, clinical vignette-based, advanced reasoning
Edition 2026 — Reflects Current DSM-5-TR, APA, FDA, and Evidence-Based Guidelines
NR 547 Advanced Psychopathology & Psychopharmacology | Page 1 | © Chamberlain PMHNP Study Series
,NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
HOW TO USE THIS EXAM PREP
• Each question is written at the advanced clinical reasoning level expected on the Chamberlain NR 547 Midterm and Final
Examinations.
• Read each vignette carefully before selecting an answer. Clinical scenarios include labs, vitals, DSM-5-TR criteria, and
comorbidities.
• The correct answer (highlighted in green with ✔) is followed by a detailed RATIONALE explaining the clinical reasoning for
correct and incorrect choices.
• A CLINICAL PEARL after each question provides high-yield exam anchors, drug comparison tables, and
DSM-5-TR/guideline references.
• All content reflects current DSM-5-TR criteria, APA Practice Guidelines, FDA approvals, SAMHSA recommendations, and
major psychiatric literature (2026).
CONTENT DOMAINS — MIDTERM & FINAL
Exam Section Content Domain Questions
Midterm Psychiatric Assessment & Differential Diagnosis Q1, Q29
Midterm Psychopharmacology — Antidepressants & Safety Q2, Q13
Midterm Bipolar Spectrum & Mood Stabilizers Q3
Midterm Schizophrenia & First-Episode Psychosis Q4
Midterm Anxiety Disorders — GAD, PTSD, OCD Q5, Q6, Q11
Midterm ADHD — Adult Diagnosis & Management Q7
Midterm Personality Disorders — BPD & DBT Q8
Midterm Substance Use Disorders — MOUD & OUD Q9
Midterm Neurocognitive Disorders — BPSD Q10
Midterm Child & Adolescent Psychiatry — ASD Q12
Midterm Legal/Ethical — Tarasoff & Duty to Protect Q14
Midterm Reproductive Psychiatry — Perinatal Mental Health Q15
Final Antipsychotic Metabolic Syndrome Management Q16
Final Suicide Risk Assessment & Crisis Intervention Q17
Final Treatment-Resistant Depression — Esketamine Q18
Final Perimenopausal/Late-Life Depression Q19
Final Clozapine REMS & Monitoring Q20
NR 547 Advanced Psychopathology & Psychopharmacology | Page 2 | © Chamberlain PMHNP Study Series
,NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
Final Tourette's Disorder & Tic Disorders Q21
Final Sleep Disorders — CBT-I & Orexin Antagonists Q22
Final Geriatric Psychiatry — Delirium vs. Psychosis Q23
Final Consultation-Liaison — Drug Interactions Q24
Final Cultural Psychiatry & CFI Q25
Final Lithium Toxicity & Emergency Management Q26
Final Group Therapy — Crisis & Yalom Factors Q27
Final Collaborative Care Model (CoCM) Q28
Final Advanced Differential — FTD Pharmacotherapy Q29
Final NMS — Recognition & Emergency Management Q30
■ MIDTERM EXAM QUESTIONS (Q1 – Q15) | Advanced Clinical Reasoning
● CATEGORY: PSYCHIATRIC ASSESSMENT & DIAGNOSTIC REASONING
Q1 [MIDTERM] A 34-year-old female presents with a 3-week history of depressed mood,
anhedonia, 12-pound weight loss, early morning awakening, psychomotor retardation,
fatigue, and recurrent thoughts of death without active suicidal plan. She denies any
prior manic or hypomanic episodes. PHQ-9 score is 22 (severe). Which DSM-5-TR
diagnosis is MOST accurate, and what specifier applies?
CLINICAL SCENARIO: PMH: None. No current medications. No substance use. TSH, CBC, CMP
all within normal limits. No psychotic features.
A) Persistent Depressive Disorder (Dysthymia) with anxious distress specifier — chronicity without
episodic course
✔ B) Major Depressive Disorder, Single Episode, Severe, with melancholic features
C) Bipolar II Disorder, current episode depressed — must rule out before diagnosing MDD
D) Adjustment Disorder with Depressed Mood — triggered by unidentified psychosocial stressor
✔ CORRECT ANSWER: B
DETAILED RATIONALE:
This patient meets full DSM-5-TR criteria for Major Depressive Episode (MDE): 5+ symptoms present nearly
every day for >2 weeks including depressed mood AND anhedonia (core symptoms), plus weight loss,
NR 547 Advanced Psychopathology & Psychopharmacology | Page 3 | © Chamberlain PMHNP Study Series
, NR 547 PMHNP | Chamberlain University | Midterm & Final Exam Prep 2026 | Advanced Psychopathology & Psychopharmacology
insomnia (early morning awakening), psychomotor retardation, fatigue, and recurrent thoughts of death.
PHQ-9 of 22 = severe. The presence of melancholic features is indicated by: (1) loss of pleasure in nearly all
activities (anhedonia), (2) lack of mood reactivity, (3) early morning awakening, (4) psychomotor retardation,
(5) significant anorexia/weight loss, and (6) distinct quality of depressed mood (qualitatively different from
grief). These features warrant the 'with melancholic features' specifier. Persistent Depressive Disorder
requires ≥2 years of depressed mood (not 3 weeks). Bipolar II requires documented hypomanic episodes —
the history denies these (though ruling out is clinically important, the answer reflects the correct diagnosis
given available information). Adjustment Disorder requires an identifiable stressor AND symptoms that do
not meet criteria for another disorder — this patient meets full MDE criteria.
★ CLINICAL PEARL & EXAM TIP: DSM-5-TR MDE = 5+ symptoms, ≥2 weeks, including depressed mood
AND/OR anhedonia. Melancholic specifier = anhedonia + ≥3 of: distinct mood quality, mood worse in AM, early
morning awakening (≥2h early), marked psychomotor change, significant anorexia/weight loss, excessive guilt.
PHQ-9 severity: 5–9=mild, 10–14=moderate, 15–19=moderately severe, ≥20=severe.
● CATEGORY: PSYCHOPHARMACOLOGY — ANTIDEPRESSANTS
Q2 [MIDTERM] A 28-year-old male with MDD, severe, is started on sertraline 50 mg daily.
At his 2-week follow-up, he reports no improvement in mood but notes significant
improvement in sleep and appetite. His Columbia Suicide Severity Rating Scale
(C-SSRS) score has increased from baseline. He reports 'I finally have enough energy to
do something about how I feel.' Which of the following MOST accurately describes this
clinical situation and the PMHNP's priority action?
CLINICAL SCENARIO: C-SSRS: Ideation intensity increased. No specific plan reported at
intake. Energy reportedly improved before mood.
A) This is expected SSRI activation — reassure the patient and continue sertraline at the current
dose
✔ B) This represents a dangerous transition window: energy recovery preceding mood
recovery increases suicide risk; perform immediate risk stratification, safety planning, and
consider hospitalization
C) The sertraline is likely not working — switch immediately to venlafaxine XR, an SNRI with faster
onset
D) Add a benzodiazepine for anxiety and schedule follow-up in 4 weeks as sertraline requires 6–8
weeks for full effect
✔ CORRECT ANSWER: B
DETAILED RATIONALE:
NR 547 Advanced Psychopathology & Psychopharmacology | Page 4 | © Chamberlain PMHNP Study Series
